Related Experiment Videos
Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2
L H Caldera1, M Leon-Ponte, G Acquatella
1Clinical Immunology Centre, University Hospital, Venezuela.
Insights
Natural killer (NK) cell activity in lymphoma patients was comparable to controls initially. However, interleukin-2 (IL-2) significantly enhanced NK cell responses, particularly in bone marrow, suggesting therapeutic potential for lymphoma treatment.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Natural killer (NK) cells are crucial for immune surveillance against cancer.
- Lymphomas, including Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL), are cancers of the lymphatic system.
- Understanding NK cell function in lymphoma patients is vital for developing novel therapies.
Purpose of the Study:
- To investigate natural killer (NK) cytotoxic activity in bone marrow mononuclear cells (BMMC) and peripheral blood lymphocytes (PBL) of untreated Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) patients.
- To evaluate the effect of recombinant human interleukin-2 (rIL-2) on NK cell activity in these patients compared to healthy controls.
- To identify the specific NK cell populations involved in the response to IL-2 stimulation.
Main Methods:
- Simultaneous assessment of NK cell cytotoxic activity in BMMC and PBL from HD, NHL patients, and healthy controls.
- NK cell activity measured under basal conditions and after stimulation with rIL-2.
- Flow cytometry and negative selection using monoclonal antibodies (MoAb) to characterize responder NK cell populations (CD3-, CD16+, CD56+).
Main Results:
- Basal NK cell activity in BMMC and PBL was comparable between lymphoma patients (HD and NHL) and healthy controls.
- Recombinant IL-2 significantly enhanced NK cell activity in PBL from all groups.
- Bone marrow NK cells from most HD and NHL patients showed a greater response to rIL-2 compared to controls.
- Responder cells were identified as CD3-, CD16+, CD56+ cytotoxic lymphocytes.
Conclusions:
- IL-2 stimulation significantly enhances NK cell activity in lymphoma patients, particularly in the bone marrow.
- The enhanced response of bone marrow NK cell precursors to IL-2 suggests a potential therapeutic role for IL-2 in lymphoma treatment.
- IL-2 may be a valuable therapeutic agent for lymphoma by activating both circulating NK cells and bone marrow NK cell precursors.
Abstract:
Natural killer (NK) cytotoxic activity was simultaneously investigated in bone marrow mononuclear cells (BMMC) and peripheral blood lymphocytes (PBL) from nine Hodgkin's disease (HD) and 15 non-Hodgkin lymphoma (NHL) untreated patients. Twenty-five PBL samples and seven bone marrow specimens from healthy individuals were also included as control group (C). NK cell activity was evaluated in basal condition and post-stimulation with human recombinant IL-2 (rIL-2). Data were expressed in K values (number of BMMC or PBL needed to lyse 50% of the target cells). In basal condition, both HD and NHL patients showed a NK cell activity comparable to the C group, both in BMMC (HD, K = 2.48 +/- 1.3; NHL, K = 3.8 +/- 2.0; C, K = 3.2 +/- 0.7) and PBL (HD, K = 2.0 +/- 1.0; NHL, K = 2.3 +/- 1.0; C, K = 2.2 +/- 0.2). Stimulation with rIL-2 induced a significant and comparable enhancement of the NK activity in PBL from HD, NHL and C while the response to rIL-2 of the BMMC in most of the HD and NHL patients was significantly greater than the C group. Responder cells were characterized by negative selection with specific MoAb plus complement as a CD3-, CD16+, CD56+ cytotoxic cell and further confirmed by flow cytometry. We postulate that IL-2 activation of bone marrow NK cell precursors, in addition to enhancing the activity of circulating NK, may be of value for the therapeutic rationale of IL-2 in patients with lymphoma.